Breakthrough: The Pontifical Council for Culture and NeoStem Partner to Advance Adult Stem Cell Research

The Vatican's Council Starts Collaboration with $1M Undertaking

NEW YORK, May 26 /PRNewswire-FirstCall/ -- In a press briefing in New York, Reverend Tomasz Trafny of the Vatican's Pontifical Council for Culture announced what he characterized as the Vatican's first-ever contractual collaboration with an outside commercial venture to advance stem cell research – adult stem cell research. Reverend Trafny also revealed that the Pontifical Council for Culture through its charitable foundation STOQ International, is making an economic commitment of one million dollars to start its collaboration with NeoStem (NYSE Amex: NBS), an international biopharmaceutical company with operations in the US and China.  Dr. Robin Smith, CEO of NeoStem, made the announcement along with Reverend Trafny.

(Photo: http://www.newscom.com/cgi-bin/prnh/20100526/NY11494 )

This initiative will partner NeoStem's and the Vatican's charitable organizations to expand research and raise awareness of adult stem cell therapies.  The initiative will entail work on a variety of collaborative activities with the goal of advancing scientific research on adult stem cells and exploring their clinical application in the field of regenerative medicine, as well as the cultural impact of such research.

NeoStem acquired the worldwide exclusive rights to VSEL™ technology in 2007. Very small embryonic-like stem cells, which form the basis of the VSEL™ technology, have physical characteristics typically found in embryonic stem cells, including the ability to differentiate into specialized cells found in different types of tissue that would be able to interact with the specific organ in order to repair degenerated, damaged or diseased tissue.  This technology addressed in this collaboration with the Vatican opens the door to the possibility of achieving the positive benefits associated with embryonic stem cells without the ethical or moral dilemmas as well as other negative effects associated with embryonic stem cells. 

"For more than 40 years, physicians have been using adult stem cells to treat various blood cancers, but only recently has the promise of using adult stem cells to treat a significant number of other diseases begun to be realized. There are tremendous clinical and economic advantages to autologous stem cell transplantation (receiving your own stem cells) as there are no issues with immune rejection. Engraftment with your own stem cells is faster, safer and much less costly than receiving someone else's stem cells (allogeneic)," said Dr. Robin L. Smith, Chairman and CEO of NeoStem. "Providing critical support to drive research and therapy efforts, this commitment is a milestone for the field of regenerative medicine," added Dr. Smith.

In addition to the breakthrough research expected to  occur as part of this partnership, the Vatican and NeoStem will spearhead an education campaign geared towards generating awareness of the cultural relevance of such a fundamental shift in medical treatment options, particularly with regard to the impact on theological and ethical issues.

Specifically, NeoStem and the Pontifical Council intend to  pursue the development of educational programs, publications and academic courses with an interdisciplinary approach for theological and philosophical faculties, including those of bioethics, around the world.

One of the highlights of this partnership will be a three day International Conference at the Vatican on adult stem cell research, including VSEL™ technology, that will focus on medical research presentations and theological and philosophical considerations and implications of scientific achievements that is planned for November 2011.

The charitable organizations from both partners that specifically will drive activity are NeoStem's Stem for Life Foundation, and the Pontifical Council's Foundation, called STOQ International(Science Theology and the Ontological Quest).

Considering the potential implication of scientific investigation, medical applicability and the cultural impact of research on adult stem cells, we view the collaboration with NeoStem as a critical effort," said Trafny. "Through educational initiatives with NeoStem and sponsorship of scientific research programs involving cutting edge adult stem cell science which does not hurt human life, we come one step closer to a breakthrough that can relieve needless human suffering. We are particularly excited about NeoStem's VSEL™ technology and believe that mutual collaboration between NeoStem and the Pontifical Council for Culture could lead to significant financial commitment to support VSEL™ technology research."

All initiatives will aim at providing information, teaching and research regarding important issues of human health and of the present and future of medical progress in relation to adult stem cell research and with respect to the great value of human life. NeoStem and the Pontifical Council for Culture through their collaboration aspire to reach religious leaders and academicians working in the Pontifical and Catholic Institutions but also to extend their work and results to different institutions beyond the catholic environment.

About NeoStem, Inc.

NeoStem, Inc. is engaged in the development of stem cell-based therapies, pursuit of anti-aging initiatives and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL(TM) technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com.

About Pontifical Council for Culture

The Pontifical Council for Culture is that Dicastery of the Roman Curia which assists the Pontiff in the exercise of his supreme pastoral office for the benefit and service of the universal Church and of particular Churches concerning the encounter between the saving message of the Gospel and cultures, in the study of the weighty phenomena of the rift between the Gospel and cultures; indifference in matters of religion; unbelief. It is also concerned with relationships between the Church and the Holy See and the world of culture; in particular it promotes dialogue with contemporary cultures, so that human civilization may become increasingly open to the Gospel, and so that men and women of science, letters and the arts may know that the Church acknowledges their work as a service to truth, goodness and beauty.

Among different tasks that have been given to the Pontifical Council for Culture, some are related to the collaboration with different cultural and scientific institutions. Those tasks are the following:

- To co-operate with Catholic universities and international organisations of a historical, philosophical, theological, scientific, artistic or intellectual nature, and to promote co-operation amongst them (John Paul II, Personal Letter to the Cardinal Secretary of State, 20 May 1982 concerns foundation of the Pontifical Council for Culture).

- To keep up with the activities of international bodies like UNESCO and the Council of Europe, which are concerned with culture, the philosophy of science and human sciences, and to ensure the effective participation of the Holy See in international congresses concerned with science, culture and education (Cf. ibid.).

- To facilitate Church-culture dialogue at the level of universities and research centres, organisations of artists and specialists, researchers and scholars, and to promote meetings of note in and through these sectors of culture (Cf. ibid.).

Forward-Looking Statements of NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the initiatives surrounding the collaboration with the Pontifical Council for Culture about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010, as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.


NEOSTEM, INC.

420 Lexington Avenue

Suite 450

New York, New York 10170

Telephone: 212-584-4180

www.neostem.com


Rubenstein Public Relations

Contact: John McCook, Tel: 212-843-8365

Email: [email protected]



SOURCE NeoStem, Inc.

Suggested Articles

The proceeds will push its lead asset, repotrectinib, into phase 2 studies and to advance a pair of earlier-stage programs in advanced solid tumors.

The latest setback saw the Novartis-partnered liver disease drug fail to beat placebo in NASH patients, wiping another 50% off Conatus’ stock price.

Eisai is starting new trials for BAN2401, just 24 hours after dumping phase 3 trials of aducanumab.